Budesonide induces complete remission in autoimmune hepatitis

World Journal of Gastroenterology

Volumn 12, Issue 9, 2006, Pages 1362-1366

  Csepregi, Antal ^a   Röcken, Christoph ^a   Treiber, Gerhard ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Adverse events; Autoimmune hepatitis; Budesonide; Complete remission

Indexed keywords

AZATHIOPRINE; BUDENOFALK; PREDNISONE; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ACNE; ACUTE HEPATITIS; ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; BODY WEIGHT DISORDER; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CUSHINGOID SYNDROME; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LIVER CIRRHOSIS; LIVER FIBROSIS; MALE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REMISSION; TREATMENT FAILURE; WEIGHT GAIN;

EID: 33645533253     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i9.1362     Document Type: Article

References (9)

1. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120: 1502-1517
2. Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, Vergani D, Vierling J, Zeniya M. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005; 41: 207-215
3. Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485-518
4. Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm Venereol Suppl (Stockh) 1989; 151: 11-9; discussion 47-52
5. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, Chapman RW, Cooksley WG, Czaja AJ, Desmet VJ, Donaldson PT, Eddleston AL, Fainboim L, Heathcote J, Homberg JC, Hoofnagle JH, Kakumu S, Krawitt EL, Mackay IR, MacSween RN, Maddrey WC, Manns MP, McFarlane IG, Meyer zum Buschenfelde KH, Zeniya M. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-938
6. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699
7. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202
8. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-590
9. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-1316